The Case for Outsourcing Biologics Process Development - Four reasons why outsourcing may be the best option, and key factors to consider when selecting a provider. - BioPharm International

ADVERTISEMENT

The Case for Outsourcing Biologics Process Development
Four reasons why outsourcing may be the best option, and key factors to consider when selecting a provider.


BioPharm International
Volume 21, Issue 12

REFERENCES

1. PriceWaterhouseCoopers. Pharma 2020: The Vision—Which Path Will You Take? London: PriceWaterhouseCoopers.2007

2. Visiongain. The World Biotech Market 2005—A visiongain report. London: Visiongain. 2007

3. Viswanathan S. A year of deals, partnering and growth. Pharm Form Qual. 2005 October;7(6):22–26.

4. John Jackson RM. Macroeconomics. Roseville, NSW: McGraw-Hill Book Company Australia Pty Ltd; 2001.

5. Aranha H, Wheelwright SM. . Transition from business process outsourcing to knowledge process outsourcing. BioPharm Int. 2007 May supplement: Guide to Outsourcing; p. 58–62.

6. Datamonitor. R&D Strategies. London: Datamonitor. 2007.

7. Bingham J. Global CROs are product development partners. Melbourne: Kendle International Inc. 2007 [cited 2007 Dec 11]. Available from: http://www.biomelbourne.org/1113.98.html.

8. Downey W. Biopharmaceutical contractor selection. Contract Pharma. 2007 April;58–63.

9. Hieber D. Six essential qualities of a bio-outsourcing partner. Contract Pharma. 2007 April;64–71.

10. BioPlan Associates. 4th annual report and survey of biopharmaceutical manufacturing capacity and production. A study of biotherapeutics developers and contract manufacturing organizations. Rockville, MD: BioPlan Associates; 2006.

11. Shahani S. Business opportunity report. Pharmaceutical contract manufacturing and research. Norwalk, CT: Business Communications Company; 2005.

12. Langer ES. Biopharmaceutical production outsourcing matures. Greater percentage of biomanufacturers contracting out for flexibility. BioProcess Int. 2007 Feb;. 32–37.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Novartis Sells Influenza Vaccine Business to CSL for $275 Million
October 27, 2014
Author Guidelines
Source: BioPharm International,
Click here